Armed with phase 3 data, Roche preps filing for Polivy in fi...

Roche has the results it was hoping for in a phase 3 trial of Polivy in newly diagnosed diffuse large B-cell lymphoma (DLBCL) – an indication it thinks could be worth up to $2 billion.

After a nay from NICE, Scotland says aye to J&J’s Spravato

NHS patients with treatment-resistant depression in Scotland will be able to access Johnson & Johnson’s Spravato, a drug that has been turned down twice by NICE for patients in England.

NICE recommends regular NHS funding for Roche's lymphoma dru...

NICE has recommended regular NHS funding for Roche’s Polivy in certain lymphoma patients in final draft guidance, overturning a previous rejection.

Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP a...